{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:42:11Z","timestamp":1793889731732,"version":"4.8.0"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007300","name":"China Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually diagnosed in advanced stages due to late symptom manifestation with very limited therapeutic options, which leads to ineffective intervention and dismal prognosis. For a decade, tyrosine kinase inhibitors (TKIs) have offered an overall survival (OS) benefit when used in a first-line (sorafenib and lenvatinib) and second-line setting (regorafenib and cabozantinib) in advanced HCC, while long-term response remains unsatisfactory due to the onset of primary or acquired resistance. Recently, immunotherapy has emerged as a promising therapy in the treatment of several solid tumors, such as melanoma and non-small cell lung cancer. Moreover, as the occurrence of HCC is associated with immune tolerance and immunosurveillance escape, there is a potent rationale for employing immunotherapy in HCC. However, immunotherapy monotherapy, mainly including immune checkpoint inhibitors (ICIs) that target checkpoints programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and the cytotoxic T lymphocyte antigen-4 (CTLA-4), has a relatively low response rate. Thus, the multi-ICIs or the combination of immunotherapy with other therapies, like antiangiogenic drugs and locoregional therapies, has become a novel strategy to treat HCC. Combining different ICIs may have a synergistical effect attributed to the complementary effects of the two immune checkpoint pathways (CTLA-4 and PD-1\/PD-L1 pathways). The incorporation of antiangiogenic drugs in ICIs can enhance antitumor immune responses\n                    <jats:italic>via<\/jats:italic>\n                    synergistically regulating the vasculature and the immune microenvironment of tumor. In addition, locoregional treatments can improve antitumor immunity by releasing the neoplasm antigens from killed tumor cells; in turn, this antitumor immune response can be intensified by immunotherapy. Therefore, the combination of locoregional treatments and immunotherapy may achieve greater efficacy through further synergistic effects for advanced HCC. This review aims to summarize the currently reported results and ongoing trials of the ICIs-based combination therapies for HCC to explore the rational combination strategies and further improve the survival of patients with HCC.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2021.783236","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T23:48:45Z","timestamp":1638316125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":164,"title":["Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Rui","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937","article-title":"Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1499-3872(16)60097-8","article-title":"Progress in Surgical and Nonsurgical Approaches for Hepatocellular Carcinoma Treatment","volume":"15","author":"Yegin","year":"2016","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0229-4","article-title":"Tumour Evolution in Hepatocellular Carcinoma","volume":"17","author":"Craig","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2019.114428","article-title":"Targeted Therapy for Hepatocellular Carcinoma: Challenges and Cpportunities","volume":"460","author":"Chen","year":"2019","journal-title":"Cancer Lett"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.09.051","article-title":"Targeted and Immune-Based Therapies for Hepatocellular Carcinoma","volume":"156","author":"Greten","year":"2019","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4004","article-title":"Results of KEYNOTE-240: Phase 3 Study of Pembrolizumab (Pembro) vs Best Supportive Care (BSC) for Second Line Therapy in Advanced Hepatocellular Carcinoma (HCC)","volume":"37","author":"Finn","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1\/2 Dose Escalation and Expansion Trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.09.025","article-title":"Challenges of Combination Therapy With Immune Checkpoint Inhibitors for Hepatocellular Carcinoma","volume":"72","author":"Cheng","year":"2020","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient-Reported Outcomes With Atezolizumab Plus Bevacizumab Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (IMbrave150): An Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0026","article-title":"Atezolizumab in Advanced Hepatocellular Carcinoma: Good Things Come to Those Who Wait","volume":"13","author":"Rizzo","year":"2021","journal-title":"Immunotherapy"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0986","article-title":"Immune-Based Combinations for Advanced Hepatocellular Carcinoma: Shaping the Direction of First-Line Therapy","volume":"17","author":"Rizzo","year":"2021","journal-title":"Future Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and Management of Hepatocellular Carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ni.2691","article-title":"Immune Surveillance by the Liver","volume":"14","author":"Jenne","year":"2013","journal-title":"Nat Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.semcancer.2014.01.004","article-title":"Virus Associated Malignancies: The Role of Viral Hepatitis in Hepatocellular Carcinoma","volume":"26","author":"Shlomai","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14192","article-title":"Immune Landscape of Hepatocellular Carcinoma Microenvironment: Implications for Prognosis and Therapeutic Applications","volume":"39","author":"Cariani","year":"2019","journal-title":"Liver Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13046-021-01873-2","article-title":"Potential Therapeutic Targets in the Tumor Microenvironment of Hepatocellular Carcinoma: Reversing the Protumor Effect of Tumor-Associated Macrophages","volume":"40","author":"Zhou","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/CritRevOncog.2020034987","article-title":"Significance of the Tumor Microenvironment in Liver Cancer Progression","volume":"25","author":"Muppala","year":"2020","journal-title":"Crit Rev Oncog"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.56003","article-title":"The Role of Tumor-Associated Macrophages in Primary Hepatocellular Carcinoma and Its Related Targeting Therapy","volume":"18","author":"Deng","year":"2021","journal-title":"Int J Med Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1333213","DOI":"10.1080\/2162402X.2017.1333213","article-title":"Colony-Stimulating Factor-1-Induced AIF1 Expression in Tumor-Associated Macrophages Enhances the Progression of Hepatocellular Carcinoma","volume":"6","author":"Cai","year":"2017","journal-title":"Oncoimmunology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"187204","DOI":"10.1155\/2013\/187204","article-title":"The Inflammatory Microenvironment in Hepatocellular Carcinoma: A Pivotal Role for Tumor-Associated Macrophages","volume":"2013","author":"Capece","year":"2013","journal-title":"BioMed Res Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting Tumor-Associated Macrophages in Cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41467-017-00530-7","article-title":"Hypoxia Inducible Factor HIF-1 Promotes Myeloid-Derived Suppressor Cells Accumulation Through ENTPD2\/CD39L1 in Hepatocellular Carcinoma","volume":"8","author":"Chiu","year":"2017","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.06.010","article-title":"Regulation of Accumulation and Function of Myeloid Derived Suppressor Cells in Different Murine Models of Hepatocellular Carcinoma","volume":"59","author":"Kapanadze","year":"2013","journal-title":"J Hepatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314032","article-title":"Hepatoma-Intrinsic CCRK Inhibition Diminishes Myeloid-Derived Suppressor Cell Immunosuppression and Enhances Immune-Checkpoint Blockade Efficacy","volume":"67","author":"Zhou","year":"2018","journal-title":"Gut"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2017.01.008","article-title":"Interactions Between Interleukin-6 and Myeloid-Derived Suppressor Cells Drive the Chemoresistant Phenotype of Hepatocellular Cancer","volume":"351","author":"Xu","year":"2017","journal-title":"Exp Cell Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3232","article-title":"Increased Populations of Regulatory T Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma","volume":"65","author":"Ormandy","year":"2005","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3381","article-title":"Higher Frequencies of GARP(+)CTLA-4(+)Foxp3(+) T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients are Associated With Impaired T-Cell Functionality","volume":"73","author":"Kalathil","year":"2013","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00482","article-title":"Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress","volume":"6","author":"Hasmim","year":"2015","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12876","article-title":"Endoplasmic Reticulum Stress Induced LOX-1(+ ) CD15(+) Polymorphonuclear Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma","volume":"154","author":"Nan","year":"2018","journal-title":"Immunology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317257","article-title":"Targeting Monocyte-Intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma","volume":"69","author":"Liu","year":"2020","journal-title":"Gut"},{"key":"B33","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/hep.23054","article-title":"Myeloid Derived Suppressor Cells Inhibit Natural Killer Cells in Patients With Hepatocellular Carcinoma via the NKp30 Receptor","volume":"50","author":"Hoechst","year":"2009","journal-title":"Hepatology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2014.08.038","article-title":"Regulatory CD4+ T Cells Modulate the Interaction Between NK Cells and Hepatic Stellate Cells by Acting on Either Cell Type","volume":"62","author":"Langhans","year":"2015","journal-title":"J Hepatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3390\/biomedicines9091277","article-title":"Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development","volume":"9","author":"Rotte","year":"2021","journal-title":"Biomedicines"},{"key":"B36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-Inhibitory Receptors With Specialized Functions in Immune Regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.601240","article-title":"Immune Checkpoint Inhibitors in the Treatment of HCC","volume":"10","author":"Donisi","year":"2020","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed Death-1 Ligand 1 Interacts Specifically With the B7-1 Costimulatory Molecule to Inhibit T Cell Responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.01.018","article-title":"Quorum Regulation via Nested Antagonistic Feedback Circuits Mediated by the Receptors CD28 and CTLA-4 Confers Robustness to T Cell Population Dynamics","volume":"52","author":"Zenke","year":"2020","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2018.08.010","article-title":"Revealing the Atomistic Details Behind the Binding of B7-1 to CD28 and CTLA-4: A Comprehensive Protein-Protein Modelling Study","volume":"1862","author":"Ganesan","year":"2018","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e002591","DOI":"10.1136\/jitc-2021-002591","article-title":"Mechanisms of Regulatory T Cell Infiltration in Tumors: Implications for Innovative Immune Precision Therapies","volume":"9","author":"Nishikawa","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130579","article-title":"Fc-Dependent Depletion of Tumor-Infiltrating Regulatory T Cells Co-Defines the Efficacy of Anti-CTLA-4 Therapy Against Melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12703","article-title":"Expression and Prognostic Significance of Programmed Death Protein 1 and Programmed Death Ligand-1, and Cytotoxic T Lymphocyte-Associated Molecule-4 in Hepatocellular Carcinoma","volume":"125","author":"Chang","year":"2017","journal-title":"Apmis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2017.03.009","article-title":"Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue Is Associated With Poor Survival After Curative Resection of Hepatocellular Carcinoma","volume":"10","author":"Dai","year":"2017","journal-title":"Transl Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.05.014","article-title":"Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-experienced Asian Cohort Analysis","volume":"71","author":"Yau","year":"2019","journal-title":"J Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.029","article-title":"CheckMate 459: A Randomized, Multi-Center Phase III Study of Nivolumab (NIVO) vs Sorafenib (SOR) as First-Line (1L) Treatment in Patients (Pts) With Advanced Hepatocellular Carcinoma (aHCC)","volume":"30","author":"Yau","year":"2019","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"Of 3","DOI":"10.1158\/2159-8290.CD-NB2017-138","article-title":"Nivolumab Approved for Liver Cancer","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib (KEYNOTE-224): A Non-Randomised, Open-Label Phase 2 Trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1159\/000500143","article-title":"Pembrolizumab for the Treatment of Hepatocellular Carcinoma","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.4071","article-title":"Safety and Clinical Activity of Durvalumab Monotherapy in Patients With Hepatocellular Carcinoma (HCC)","volume":"35","author":"Wainberg","year":"2017","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A Clinical Trial of CTLA-4 Blockade With Tremelimumab in Patients With Hepatocellular Carcinoma and Chronic Hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00262-019-02299-8","article-title":"The Effect of Anti-CTLA4 Treatment on Peripheral and Intra-Tumoral T Cells in Patients With Hepatocellular Carcinoma","volume":"68","author":"Agdashian","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of Peripheral T-Cell Tolerance and Autoimmunity via the CTLA-4 and PD-1 Pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination Therapy With Anti\u2013CTLA-4 and Anti\u2013PD-1 Leads to Distinct Immunologic Changes In Vivo","volume":"194","author":"Das","year":"2015","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.4073","article-title":"Phase I\/II Study of Durvalumab and Tremelimumab in Patients With Unresectable Hepatocellular Carcinoma (HCC): Phase I Safety and Efficacy Analyses","volume":"35","author":"Kelley","year":"2017","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"TPS4144","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4144","article-title":"A Randomized, Multicenter Phase 3 Study of Durvalumab (D) and Tremelimumab (T) as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma (HCC): HIMALAYA Study","volume":"36","author":"Abou-Alfa","year":"2018","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region With Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib Versus Sorafenib in First-Line Treatment of Patients With Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"212577","DOI":"10.7573\/dic.212577","article-title":"Second-Line Treatment Options in Hepatocellular Carcinoma","volume":"8","author":"Marino","year":"2019","journal-title":"Drugs Context"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30889","article-title":"Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"key":"B63","article-title":"Abstract CT061: A Phase Ib Trial of Lenvatinib (LEN) Plus Pembrolizumab (PEMBRO) in Unresectable Hepatocellular Carcinoma (uHCC): Updated Results","volume-title":"Proceedings: AACR Annual Meeting","author":"Ikeda","year":"2019"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.4075","article-title":"Anti-Programmed Death-1 Antibody SHR-1210 (S) Combined With Apatinib (A) for Advanced Hepatocellular Carcinoma (HCC), Gastric Cancer (GC) or Esophagogastric Junction (EGJ) Cancer Refractory to Standard Therapy: A Phase 1 Trial","volume":"36","author":"Xu","year":"2018","journal-title":"Ann Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03081","article-title":"Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer","volume":"9","author":"Georganaki","year":"2018","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01956","article-title":"Anti-Angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment","volume":"11","author":"Song","year":"2020","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00320","article-title":"Immunomodulation Mediated by Anti-Angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental Glioma","volume":"8","author":"Malo","year":"2018","journal-title":"Front Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A Modulates Expression of Inhibitory Checkpoints on CD8+ T Cells in Tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic Agents Can Increase Lymphocyte Infiltration Into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00061","article-title":"Control of the Adaptive Immune Response by Tumor Vasculature","volume":"4","author":"Mauge","year":"2014","journal-title":"Front Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e7669","DOI":"10.1371\/journal.pone.0007669","article-title":"Cytokine Levels Correlate With Immune Cell Infiltration After Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer","volume":"4","author":"Roland","year":"2009","journal-title":"PloS One"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nature21724","article-title":"Mutual Regulation of Tumour Vessel Normalization and Immunostimulatory Reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96582","article-title":"Increased Vessel Perfusion Predicts the Efficacy of Immune Checkpoint Blockade","volume":"128","author":"Zheng","year":"2018","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2110","article-title":"Macrophages Are Recruited to Hypoxic Tumor Areas and Acquire A Pro-Angiogenic M2-Polarized Phenotype via Hypoxic Cancer Cell Derived Cytokines Oncostatin M and Eotaxin","volume":"5","author":"Tripathi","year":"2014","journal-title":"Oncotarget"},{"key":"B76","doi-asserted-by":"publisher","first-page":"v875","DOI":"10.1093\/annonc\/mdz394.030","article-title":"Randomised Efficacy and Safety Results for Atezolizumab (Atezo)+ Bevacizumab (Bev) in Patients (Pts) With Previously Untreated, Unresectable Hepatocellular Carcinoma (HCC)","volume":"30","author":"Lee","year":"2019","journal-title":"Ann Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz446.002","article-title":"IMbrave150: Efficacy and Safety Results From A Ph III Study Evaluating Atezolizumab (Atezo)+ Bevacizumab (Bev) vs Sorafenib (Sor) as First Treatment (Tx) for Patients (Pts) With Unresectable Hepatocellular Carcinoma (HCC)","volume":"30","author":"Cheng","year":"2019","journal-title":"Ann Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.476","article-title":"Patient-Reported Outcomes (PROs) From the Phase III IMbrave150 Trial of Atezolizumab (Atezo) + Bevacizumab (Bev) vs Sorafenib (Sor) as First-Linettreatment (Tx) for Patients (Pts) With Unresectable Hepatocellular Carcinoma (HCC)","volume":"38","author":"Galle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"193","DOI":"10.21037\/hbsn.2020.03.11","article-title":"A Review on Radiofrequency, Microwave and High-Intensity Focused Ultrasound Ablations for Hepatocellular Carcinoma With Cirrhosis","volume":"10","author":"Cheung","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.3390\/cancers13122984","article-title":"Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"13","author":"Esagian","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i20.2434","article-title":"Role of Modern Radiotherapy in Managing Patients With Hepatocellular Carcinoma","volume":"27","author":"Chen","year":"2021","journal-title":"World J Gastroenterol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1159\/000449341","article-title":"Selective Internal Radiation Therapy (SIRT) as Conversion Therapy for Unresectable Primary Liver Malignancies","volume":"5","author":"Cucchetti","year":"2016","journal-title":"Liver Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic Cell Death in Cancer and Infectious Disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12885-019-5566-8","article-title":"Abscopal Effect of Radiation on Multiple Lung Metastases of Lung Adenocarcinoma: A Case Report","volume":"19","author":"Kuroda","year":"2019","journal-title":"BMC Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharmthera.2018.12.002","article-title":"Immune Mechanisms Mediating Abscopal Effects in Radioimmunotherapy","volume":"196","author":"Rodriguez-Ruiz","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00568-1","article-title":"Immunomodulation by Radiotherapy in Tumour Control and Normal Tissue Toxicity","author":"Cytlak","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6","article-title":"Using Immunotherapy to Boost the Abscopal Effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00262-013-1474-y","article-title":"Antitumor Immune Responses Induced by Ionizing Irradiation and Further Immune Stimulation","volume":"63","author":"Frey","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in Combination With Ablation in Patients With Advanced Hepatocellular Carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"xi45","DOI":"10.1093\/annonc\/mdz451.030","article-title":"Local Thermal Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Progressive Diseases During Anti-PD-1 Therapy","volume":"30","author":"Zhao","year":"2019","journal-title":"Ann Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional Therapies in the Era of Molecular and Immune Treatments for Hepatocellular Carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"v288","DOI":"10.1093\/annonc\/mdz247.076","article-title":"750pa Phase Ib Study of Pembrolizumab Following Trans-Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): PETAL","volume":"30","author":"Pinato","year":"2019","journal-title":"Ann Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.4590","article-title":"A Phase II Open-Label, Single-Center, Nonrandomized Trial of Y90-Radioembolization in Combination With Nivolumab in Asian Patients With Advanced Hepatocellular Carcinoma: CA 209-678","volume":"38","author":"Tai","year":"2020","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7753","article-title":"Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005","volume":"27","author":"Altekruse","year":"2009","journal-title":"J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer Statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3390\/cancers11101554","article-title":"Predictive Factors for Response to PD-1\/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges","volume":"11","author":"Macek Jilkova","year":"2019","journal-title":"Cancers"},{"key":"B98","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2019.12.107","article-title":"PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee","volume":"15","author":"Sylvie","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an Immune-Specific Class of Hepatocellular Carcinoma, Based on Molecular Features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.783236\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T23:48:50Z","timestamp":1638316130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.783236\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":100,"alternative-id":["10.3389\/fimmu.2021.783236"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.783236","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,26]]},"article-number":"783236"}}